Cholesterol and blood fats
Silymarinand Triglycerides
Both sources here measured lower triglycerides.
How sure anyone can be
Low certainty, level 2 of 4Further research is likely to change this.
The most certain of the two findings here; each record carries its own.
The numbers reported
One source’s range, drawn against its own line of no difference and scaled to its own numbers.
-1.14-0.62 standardised effect size-0.1
This range stays on one side of the no-difference line.
Two sources, newest first
What we read is the published abstract, not the full paper, so a blank below may still be printed in the paper itself. A fixed rule worked this out from the source’s own fields. Nobody checked this rating by hand.
Systematic review, 2024
Low certainty, level 2 of 4Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis.
Ann Hepatol. 2024;29(2):101174. doi:10.1016/j.aohep.2023.101174. PMID:38579127.
- Number reported
- -0.62 standardised effect size
- Which way it went
- Lower
- Likely range
- -1.14 to -0.1
- Source’s own words
- standardised mean difference in triglycerides vs control
- Who was studied
- Adult with NAFLD
- Compared with
- control
- Amount taken
- Not in the abstract
- For how long
- Not in the abstract
- Disagreement between studies
- Not in the abstract
- Kind of record
- Journal article
How this rating was reachedstarts at High, 2 steps down: risk of bias and imprecision
- Starts at High
- Risk of bias brought it down to Moderatethe abstract reports no risk-of-bias or quality appraisal, so study limitations cannot be ruled outNot in the abstract
- Imprecision brought it down to Lowthe abstract does not state how many participants were pooledNot in the abstract
- Ends at Low2 steps down.
- Checked, nothing to step it down for
- indirectness
- Inconsistency
- No disagreement reported, and no count of studies behind it
Imprecision stops at the first check that applies; others may apply too.
AI review could not confirm it — an AI agent re-read this finding against the saved source and at least one check failed. The batch record names the check and quotes the sentence that caused the doubt. No person read it.
Systematic review, 2024
Low certainty, level 2 of 4Impacts of Supplementation with Silymarin on Cardiovascular Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.
Antioxidants (Basel). 2024;13(4). doi:10.3390/antiox13040390. PMID:38671838.
- Number reported
- -26.22 mg/dL
- Which way it went
- Lower
- Likely range
- -40.32 to -12.12
- Source’s own words
- mg/dL triglycerides, weighted mean difference vs untreated control
- Who was studied
- Adult
- Compared with
- untreated counterparts (control groups across 33 trials)
- Amount taken
- Not in the abstract
- For how long
- Not in the abstract
- Disagreement between studies
- Not in the abstract
- Kind of record
- Journal article
How this rating was reachedstarts at High, 2 steps down: risk of bias and imprecision
- Starts at High
- Risk of bias brought it down to Moderatethe abstract reports no risk-of-bias or quality appraisal, so study limitations cannot be ruled outNot in the abstract
- Imprecision brought it down to Lowthe abstract does not state how many participants were pooledNot in the abstract
- Ends at Low2 steps down.
- Checked, nothing to step it down for
- indirectness
- Inconsistency
- No disagreement reported, and no count of studies behind it
Imprecision stops at the first check that applies; others may apply too.
AI review could not confirm it — an AI agent re-read this finding against the saved source and at least one check failed. The batch record names the check and quotes the sentence that caused the doubt. No person read it.
What is still missing from these readings
- Two do not say how many people took part.
- Amount taken — Not in the abstract.
- For how long — Not in the abstract.
Something nobody wrote down is never a zero and never a guess.
Nothing left on our list for Silymarin
All 11 things on our list for Silymarin have been read. That is rare here.
Still to read means nobody here has got to it, not that it was tried and did nothing or that no research exists. A pairing on no list is not a gap: we never set out to read it.
Read next
Silymarin
Ten other questions read for it
Cholesterol and blood fats
65 questions read under it
Triglycerides
15 other ingredients read against it
First six, alphabetical, and by nothing else. The rest are on Cholesterol and blood fats.
This is a library, not advice. No recommendation, no dose, no diagnosis, no ranking. We never ask about your symptoms, and nothing here is tailored to you.